TNYA

Tenaya Therapeutics, Inc. TNYA

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$1.11M

Quarter to Jun 30

Net income

$-43.39M

Quarter to Jun 30

Free cash flow

$-3.71M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$39.85M total
VANGUARD CAPITAL MANAGEMENT LLC
$5.25M-16.3%
MILLENNIUM MANAGEMENT LLC
$4.75M+17.8%
CITADEL ADVISORS LLC
$3.38M+8.7%
RENAISSANCE TECHNOLOGIES LLC
$3.16M+15.3%
BlackRock, Inc.
$2.96M+8.2%
Empery Asset Management, LP
$2.86M-9.9%
MARSHALL WACE, LLP
$2.59M+29.5%
GSA CAPITAL PARTNERS LLP
$1.97M+148.8%
Burkehill Global Management, LP
$1.48M0.0%
GEODE CAPITAL MANAGEMENT, LLC
$1.36M+17.6%
ADAR1 Capital Management, LLC
$1.15M+3.2%
Raiffeisen Bank International AG
$881.9K+20.0%
Euclidean Capital LLC
$750.7K0.0%
VANGUARD FIDUCIARY TRUST CO
$729.8K-2.8%
Mirador Capital Partners LP
$669.0K+2.0%
STATE STREET CORP
$523.8K0.0%
Squarepoint Ops LLC
$487.2K+89.3%
StepStone Group LP
$341.5K0.0%
UBS Group AG
$337.4K-31.4%
JANE STREET GROUP, LLC
$332.9K-61.8%
TWO SIGMA INVESTMENTS, LP
$281.4K-70.3%
Casdin Capital, LLC
$267.5K0.0%
Invesco Ltd.
$262.3K+157.1%
NORTHERN TRUST CORP
$256.0K+11.5%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$240.4K+5.4%
See all 102 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/TNYA

Earnings Per Share

13fpro.ai/company/TNYA

Loading ratio trend…

TNYA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Tenaya Therapeutics, Inc. (TNYA): stock profile, AI score and financials

Tenaya Therapeutics, Inc. (TNYA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. TNYA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Tenaya Therapeutics, Inc. reports quarterly revenue of $1.1M, net income of $-43.4M, free cash flow of $-3.7M. Top institutional holders of TNYA by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, MILLENNIUM MANAGEMENT, CITADEL ADVISORS, based on the most recent SEC filings. TNYA trades on the Nasdaq exchange and files with the SEC under CIK 1858848. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TNYA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tenaya Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1858848 →